Comparative Pharmacology
Head-to-head clinical analysis: ALA CORT versus PROCTOFOAM HC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALA CORT versus PROCTOFOAM HC.
ALA-CORT vs PROCTOFOAM HC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topical corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid, thereby reducing prostaglandin and leukotriene synthesis, and exerting anti-inflammatory, antipruritic, and vasoconstrictive effects.
Hydrocortisone is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive actions by binding to cytoplasmic glucocorticoid receptors, which then translocate to the nucleus and modulate gene expression, leading to suppression of inflammatory mediators (e.g., prostaglandins, leukotrienes) and inhibition of immune cell migration. Pramoxine is a local anesthetic that reversibly blocks sodium ion channels in nerve membranes, thereby inhibiting initiation and conduction of sensory nerve impulses.
Topical: Apply a thin film to affected area 3-4 times daily. Dosage strength: 0.5% cream or ointment.
Rectal aerosol foam: 1 applicatorful (6.5% pramoxine HCl / 1% hydrocortisone) rectally 2-3 times daily. Maximum 4 weeks.
None Documented
None Documented
Terminal elimination half-life: 1–2 hours for hydrocortisone (active component), prolonged in liver disease or with concurrent CYP3A4 inhibitors.
The terminal elimination half-life of hydrocortisone is approximately 1.5-2 hours. After topical application to the rectal mucosa, systemic absorption is minimal, resulting in a half-life comparable to that of endogenous cortisol, with clinical effects lasting about 6-8 hours.
Primarily hepatic metabolism (approximately 95%) followed by renal excretion of inactive metabolites (<5% unchanged). Biliary/fecal excretion is negligible.
Hydrocortisone is metabolized in the liver, primarily to inactive metabolites (tetrahydrocortisone and tetrahydrocortisol). Less than 1% of the dose is excreted unchanged in urine. Fecal excretion is negligible.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid